ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 90 filers reported holding ALX ONCOLOGY HLDGS INC in Q4 2020. The put-call ratio across all filers is 0.71 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $52,346 | 0.0% | 11,581 | 0.0% | 0.00% | – |
| Q1 2023 | $52,346 | -100.0% | 11,581 | -12.6% | 0.00% | – |
| Q2 2022 | $107,201,000 | -98.3% | 13,251 | -96.4% | 0.00% | -100.0% |
| Q1 2022 | $6,179,535,000 | -18.4% | 365,653 | +3.8% | 0.00% | 0.0% |
| Q4 2021 | $7,569,895,000 | -62.4% | 352,252 | +29.3% | 0.00% | -62.5% |
| Q3 2021 | $20,114,811,000 | +33.2% | 272,337 | -1.4% | 0.01% | +33.3% |
| Q2 2021 | $15,098,952,000 | +12.0% | 276,133 | +51.0% | 0.01% | 0.0% |
| Q1 2021 | $13,484,096,000 | +371.0% | 182,860 | +450.6% | 0.01% | +500.0% |
| Q4 2020 | $2,862,616,000 | – | 33,209 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |